Drug updates: December

Draft guidance, published on the 18 November, is the first time NICE has made recommendations about the use of an HIV treatment since these came under NICE's remit in 2019. It is estimated that...

Drug Updates: October

Ronapreve, a combination of two monoclonal antibodies, is the first targeted medicine developed for COVID-19 to receive marketing authorisation from the Medicines and Healthcare products Regulatory...

Drug Updates: September

Following new draft guidance from the National Institute for Health and Care Excellence (NICE), midostaurin (Rydapt, Novartis) has been recommended for the treatment of advanced systemic mastocytosis...

Drug Updates: August

Enzalutamide plus androgen deprivation therapy (ADT) is recommended by NICE, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults.

Updates: July 2021

On 10 June, the National Institute for Health and Care Excellence (NICE) published new final guidance that has recommended several new treatment options for around 25 000 people with moderate...

Updates: May 2021

The National Institute for Health and Care Excellence (NICE) announced on the 4 May 2021 that more people the rare genetic disorder spinal muscular atrophy (SMA) will be able to benefit from...

Updates: May 2021

The National Institute for Health and Care Excellence (NICE) announced on the 4 May 2021 that more people the rare genetic disorder spinal muscular atrophy (SMA) will be able to benefit from...

Drug Breakdown: carbamazepine

Day 1: #carbamazepine was discovered mid 1950s as a tricyclic compound related to imipramine and was found to be effective for trigeminal neuralgia. Animal studies showed an anti-epileptic effect,...

Drug breakdown: Clarithromycin – Earn your CPD

Updates

Hyperkalaemia is a high level of potassium in the blood, classified in three levels: mild (serum potassium level of 5.5 mmol/litre to 5.9 mmol/litre), moderate (6.0 mmol/litre to 6.4 mmol/litre) or...